GCDFP-15 CRISPR Activation Plasmid (h): sc-404430-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GCDFP-15 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- GCDFP-15 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GCDFP-15 CRISPR Activation Plasmid (h) and GCDFP-15 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PIP transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GCDFP-15 CRISPR Activation Plasmid (h) | sc-404430-ACT | 20 µg | $397.00 |
PIP encodes GCDFP-15 (prolactin-inducible protein), a secreted glycoprotein prominently expressed in apocrine-associated epithelia and regulated by steroid hormone signaling. GCDFP-15 participates in extracellular protein interactions and is commonly used as a molecular marker of epithelial differentiation states, reflecting transcriptional programs linked to hormone responsiveness. Its expression patterns are frequently evaluated in studies of breast and other glandular tissues, where altered PIP/GCDFP-15 levels correlate with changes in tumor subtype biology and cellular lineage features. As a secreted factor, GCDFP-15 also supports investigations into microenvironmental signaling and biomarker-associated pathway readouts.
GCDFP-15 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PIP expression without altering the underlying DNA sequence.
GCDFP-15 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PIP locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PIP transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GCDFP-15 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PIP locus and enabling the study of GCDFP-15-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GCDFP-15 pathway restoration in tumor cells with silenced or reduced PIP expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.